Evidence map›Paper›PMID 39331039›Full record

ArticleChemMedChem2025

α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML.

Maria Luisa Introvigne, Lorenza Destro, Luca Mologni, Valentina Crippa, Paolo Zardi, Francesco Fini, Fabio Prati, Emilia Caselli, Alfonso Zambon

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Maria Luisa IntrovigneDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Lorenza DestroDepartment of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Luca MologniDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Valentina CrippaDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Paolo ZardiDepartment of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Francesco FiniDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Fabio PratiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0002-0650-9540
Emilia CaselliDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Alfonso ZambonDepartment of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0002-8074-2308

Funding

Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
AIRC 24828Infectious Diseases of the National Institutes of Health R01AI072219National Institute of AllergyNIAID NIH HHS R01 AI072219
6 · The paper itself

Abstract

The treatment of acute myeloid leukemia (AML) presents a challenge to current therapies because of the development of drug resistance. Genetic mutation of FMS-like tyrosine kinase-3 (FLT3) is a target of interest for AML treatment, but the use of FLT3-targeting agents on AML patients has so far resulted in poor overall clinical outcomes.

Indexed as

Antineoplastic AgentsBoronic Acidsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteProtein Kinase InhibitorsTriazolesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBoronic AcidsFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsTriazolesAcute Myeloid LeukemiaBoron ChemicalFLT3 Protein Kinase

Identifiers

PMID39331039
PMCPMC11694611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.